Diabetes specialists attending the Diabetes UK Annual Professional Conference in Birmingham, UK, have called for the need to control both fasting and postprandial blood-glucose in type 2 diabetes patients. Almost half of all type 2 patients new to insulin are started on basal regimens, which aim only to improve FBG measurements and do not directly manage PPBG, according to a press statement from US drug major Eli Lilly.
The comments came during a Lilly-sponsored symposium debating different strategies used to gain optimum control of type 2 diabetes. The delegates agreed the following recommendations:
- both FBG and PPBG are important contributors to overall glycemic control/HbA1c; and
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze